ESMO

Younger Female Patients With Cancer Report Less Emotional Function

October 18th 2025, 5:46pm

Article

Among patients with solid tumors, baseline emotional functioning was moderate, with lower functioning for female and younger patients.

Imdelltra Plus Chemoimmunotherapy Safely Elicits Responses in ES-SCLC

October 18th 2025, 4:39pm

Article

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

Giredestrant/Afinitor Reduces Progression in Advanced Breast Cancer

October 18th 2025, 2:17pm

Article

In patients with ER-positive, HER2-negative advanced breast cancer, giredestrant and Afinitor reduced risk of disease progression or death.

Tagrisso Plus Chemo Offers Survival benefit in EGFR+ NSCLC

October 17th 2025, 11:52pm

Article

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

Quality of Life Maintained with Akeega Combo in Prostate Cancer

October 17th 2025, 9:28pm

Article

For patients with HRRm prostate cancer receiving Akeega with prednisone, quality of life remained at baseline.

Open-Label Extension of Ponsegromab Shows Efficacy in Cancer-Associated Cachexia

October 17th 2025, 8:47pm

Article

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Kisqali Plus Aromatase Inhibitor Shows Long-Term Benefit in Early Breast Cancer

October 17th 2025, 8:30pm

Article

Adding Kisqali to a nonsteroidal aromatase inhibitor continued to reduce recurrence risk and improve survival at five years in early breast cancer.

Imfinzi Plus Chemo Improves Survival in G/GEJ Adenocarcinoma

October 17th 2025, 8:26pm

Article

Among patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma that is resectable, Imfinzi with FLOT improved survival.

Imfinzi Plus BCG Improves Disease-Free Survival in High-Risk NMIBC

October 17th 2025, 7:40pm

Article

Adding Imfinzi to Bacillus Calmette-Guérin therapy improved disease-free survival for patients with high-risk, non-muscle invasive bladder cancer.

Imfinzi Not Associated With Bladder Cancer Quality of Life Decline

October 17th 2025, 7:39pm

Article

Among patients with muscle-invasive bladder cancer, perioperative Imfinzi to chemotherapy doesn’t have a detrimental effect on patient-reported outcomes.